The clinical evaluation of low-dose heparin in haemodialysis: A prospective study using the heparin-coated AN69 ST membrane

Nephrology Dialysis Transplantation

Volumn 23, Issue 6, 2008, Pages 2003-2009

  Chanard, Jacques ^a   Lavaud, Sylvie ^a   Maheut, Hervé ^a   Kazes, Isabelle ^a   Vitry, Fabien ^a   Rieu, Philippe ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

AN69 ST dialysis membrane; Dialysis anticoagulation; Haemodialysis; Heparin coated membrane

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; HEPARIN; SODIUM CHLORIDE;

AGED; ANTICOAGULATION; ARTICLE; ARTIFICIAL KIDNEY; BLEEDING; BLOOD CLOTTING; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS MEMBRANE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MATERIAL COATING; MORTALITY; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; THROMBOCYTE; VALIDATION STUDY;

ACRYLIC RESINS; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COATED MATERIALS, BIOCOMPATIBLE; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUIPMENT FAILURE; EQUIPMENT SAFETY; FEMALE; FOLLOW-UP STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK ASSESSMENT; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 44449167645     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm888     Document Type: Article

References (25)

1. Ouseph R, Ward RA. Anticoagulation for intermittent hemodialysis. Semin Dial 2000; 13: 181-187
2. Mulvihill J, Crost T, Renaux JL et al. Evaluation of haemodialysis membrane biocompatibility by parallel assessment in an ex vivomodel in healthy volunteers. Nephrol Dial Transplant 1997; 12: 1968-1973
3. Sagedal S, Hartmann A, Sundstrom K et al. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 2001; 16: 987-993
4. Jubelirer SJ. Hemostatic abnormalities in renal disease. Am J Kidney Dis 1985; 5: 219-225
5. Ambuhl PM, Wuthrich RP, Korte W et al. Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation. Nephrol Dial Transplant 1997; 12: 2355-2364
6. Ridel C, Mercadal L, Bene B et al. Regional citrate anticoagulation during hemodialysis. Blood Purif 2005; 23: 473-480
7. Sagedal S, Hartmann A, Osnes K et al. Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin. Nephrol Dial Transplant 2006; 21: 444-449
8. Kwan BCH, Kronenberg F, Beddhu S et al. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007; 18: 1246-1261
9. Irie A, Takami M, Kubo H et al. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 2007; 41: 165-174
10. Lucchi L, Ligabue G, Marietta M et al. Activation of coagulation during hemodialysis: effect of blood lines alone and whole extracorporeal circuit. Artif Organs 2006; 30: 106-110
11. Franck RD, Muller U, Lanzmich R et al. Anticoagulant-free Genius® haemodialysis using low molecular weight heparin-coated circuits. Nephrol Dial Transplant 2006; 21: 1013-1018
12. Urlesberger B, Zobel G, Rodl S et al. Activation of the clotting system: heparin-coated versus non coated system for extracorporeal circulation. Int J Artif Organs 1997; 20: 708-712
13. Stammers AH, Christensen KA, Lynch J et al. Quantitative evaluation of heparin-coated versus non-heparin coated bypass circuits during cardiopulmonary bypass: a meta analysis. J Extra Corpor Technol 1999; 31: 135-141
14. Mujais SK, Chimeh H. Heparin free hemodialysis using heparin-coated hemophan. Int J Artif Organs 2000; 23: 20-26
15. Mirow N, Brinkmann T, Minami K et al. Heparin-coated extracorporeal circulation with full and low dose heparinization: comparison of thrombin related coagulatory effects. Artif Organs 2001; 25: 480-485
16. Chanard J, Lavaud S, Paris B et al. Assessment of heparin binding to the AN69 ST hemodialysis membrane: I. Preclinical studies. ASAIO J 2005; 51: 342-347
17. Lavaud S, Paris B, Maheut H et al. Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration. ASAIO J 2005; 51: 348-351
18. Petitclerc T. Recent developments in conductivity monitoring of haemodialysis session. Nephrol Dial Transplant 1999; 14: 2607-2613
19. Lindsay RM, Bene B, Goux N et al. Relationship between effective ionic dialysance and in vivo urea clearance during hemodialysis. Am J Kidney Dis 2001; 38: 565-574
20. Lavaud S, Canivet E, Wuillai A et al. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane. Nephrol Dial Transplant 2003; 18: 2097-2104
21. Leblanc M, Lafrance JP, Renald A. Dialyser fiber bundle volume during hemodialysis using large-surface dialysers. ASAIO J 2006; 52: 646-651
22. Keuren JF, Wielders SJ, Willems GM et al. Fibrinogen adsorption, platelet adhesion and thrombin generation at heparinized surfaces exposed to flowing blood. Thromb Haemost 2002; 87: 742-747
23. Weber N, Wendel HP, Ziemer G. Hemocompatibility of heparin-coated surfaces and the role of selective plasma protein adsorption. Biomaterials 2002; 23: 429-439
24. Moachon N, Boullanger C, Fraud S et al. Influence of the charge of low molecular weight proteins on their efficacy of filtration and/or adsorption on dialysis membranes with different intrinsic properties. Biomaterials 2002; 23: 651-658
25. Wendel HP, Ziemer G. Coating techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. Eur J Cardiothorac Surg 1999; 16: 342-350